Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

LONDON, October 12, 2011 /PRNewswire/ --

- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).

"Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012.  Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.

ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments and also does not carry the risk of hypersensitivity reactions as is the case with currently marketed intravenous iron therapies.  Whilst prescribers often try oral ferrous products as first line therapy, many subjects prove intolerant and suffer from continuously occurring side effects, exacerbation of inflammatory lesions and failure to correct iron deficiency.  This results in the need for expensive, complicated and invasive intravenous iron therapy.  When treated with ST10, the total dose exposure of unabsorbed iron within the gastrointestinal tr
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 This report is a ... industry. For an overview analysis, the report introduces ... chain structure, industry overview, policy analysis, and news ... has witnessed rapid development with key manufacturers ... This report mentions quartz tubing upstream raw materials ...
(Date:12/17/2014)... SPRING, Md. , Dec. 17, 2014  United ... two senior executive promotions as well as changes to ... Senior Executive Promotions United Therapeutics ... to President and Co-Chief Executive Officer and David ... Operating Officer.  In connection with these promotions, Dr. Rothblatt,s ...
(Date:12/15/2014)... YORK & PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI ), a leading developer ... today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was ... Israel,s Office of the Chief Scientist ... been in receipt of grant support from the Office ...
(Date:12/13/2014)... 13, 2014 CanDiag, Inc., a University ... has changed its name to OncoTab, Inc. , ... where we are today,” said CEO and Chief Science ... applications beyond breast cancer diagnostics to include imaging and ... that evolution.” , Founded in 2011 by Dr. Mukherjee, ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... 20, 2011 Scientists Drs. Samuel and Elenore Bogoch of ... increase in Replikin Counts of the EHEC lethal strains of ... strains of E. Coli have been studied in laboratories in ... available in the public databases. Replikins are subsequences of the ...
...   Hospitals, health systems to ... Sigma and other,performance management solutions ... information products,and services, has struck an exclusive partnership with ... online learning solutions for process,improvement. Elsevier will ...
... has the potential to make consumer electronic devices faster ... scale of electronics, also make graphene difficult to fabricate ... In September 2010, a UCLA research team reported ... were able to fabricate graphene transistors with unparalleled speed. ...
Cached Biology Technology:Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 2Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 3Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a ... that its U.are.U ® fingerprint readers have been ... in Central Mexico . The bakery ... to eliminate payroll issues caused by employees clocking in ... the U.are.U fingerprint readers, Montparnasse relied on paper timecards ...
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... Jan. 7, 2013 Halting climate change will require "a ... eradicate harmful carbon dioxide emissions, not just stabilize them, according ... In a Jan. 9 paper in Environmental Research Letters ... take a fresh look at the popular "wedge" approach to ...
... from Italy and their offspring form one of the largest ... their state of health and risk of mortality. In a ... University of Zurich,s Institute of Social and Preventative Medicine calculated ... Immigrants from Italy live longer than ...
... New research led by the Karolinska Institutet, Sweden and the ... human gene and the composition of human gastrointestinal bacteria. In ... Gut , the team outline new evidence suggesting that the ... of the billions of microbes in the human gastrointestinal tract ...
Cached Biology News:Major cuts to surging CO2 emissions are needed now, not down the road, study finds 2Italian immigrants live longer 2International study suggests human genes influence gut microbial composition 2
... The Jouan MSC series of Class ... working conditions and certification to the ... regulation ensures that the cabinets cannot ... conditions. Natural lighting, low noise and ...
... a dedicated fluorometer with sensitivity ... of assays in industrial and ... applications. Cell biology, immunology and ... application areas. Robot-friendly hardware and ...
... The Holten MaxiSafe 2010 Class ... most ergonomical working condition of comfort ... safety, efficiency and performance.,Refined operator, environment ... of both exhausted and recirculated air.,Bottom ...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
Biology Products: